Bachem Holding AG (LON:0QND)

Market Cap	5.44B +62.9%
Revenue (ttm)	651.29M +14.8%
Net Income	139.42M +23.7%
EPS	1.86 +23.8%
Shares Out	n/a
PE Ratio	39.02
Forward PE	30.91
Dividend	0.85 (1.06%)
Ex-Dividend Date	May 4, 2026

Volume	33,755
Average Volume	35,124
Open	77.80
Previous Close	77.44
Day's Range	76.53 - 78.55
52-Week Range	48.32 - 83.25
Beta	0.78
RSI	62.13
Earnings Date	Jul 30, 2026

About Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, an...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1971
• Employees: 2,595
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QND

Financial Performance

In 2025, Bachem Holding AG's revenue was 695.07 million, an increase of 14.84% compared to the previous year's 605.26 million. Earnings were 148.79 million, an increase of 23.74%.

Financial numbers in CHF